← All trials
NCT00501618
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2006
- Primary completion
- Mar 1, 2009
- Completion date
- Jul 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Manhattan Psychiatric CenterLead sponsor
- Manhattan Psychiatric CenterOverall official - principal investigator
- New York UniversityStudy chair
- Azur Pharma, IncCollaborator
- Manhattan Psychiatric CenterReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.